8-K: ATAI Life Sciences to Acquire Beckley Psytech, Forming Psychedelic Mental Health Powerhouse 'Atai Beckley' with $30M Concurrent Financing

ATAI Life Sciences announced a definitive agreement to acquire Beckley Psytech in an all-share transaction, creating a market-leading mental health company with a synergistic pipeline and a concurrent $30 million private placement.

Summary

• ATAI Life Sciences will acquire the remaining issued share capital of Beckley Psytech Limited not already owned by atai through an all-share transaction.
• Beckley Psytech shareholders (excluding atai) will receive approximately 105,044,902 new atai ordinary shares, equating to approximately 31% of the combined company on a fully diluted basis.
• The transaction values Beckley Psytech at approximately $390 million.
• A concurrent private placement (PIPE Financing) of approximately $30 million was executed with Ferring Ventures S.A. and Adage Capital Partners LP.
• The PIPE Financing involves the purchase of 9,993,341 Common Shares at $1.84 per share and a pre-funded warrant to purchase 6,311,006 Common Shares with an exercise price of $0.01, for a purchase price of $1.84 per underlying share less the exercise price.
• Proceeds from the PIPE Financing are designated for general corporate purposes and will not be used to finance the acquisition.
• Beckley Psytech's clinical-stage asset ELE-101 (psilocin for Major Depressive Disorder) and its related funding/assets will be carved out from the Beckley Group prior to the acquisition's closing.
• The combined entity is expected to operate under the new name 'Atai Beckley N.V.'.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook on the strategic acquisition, emphasizing market leadership, synergistic pipeline, near-term clinical milestones, financial synergies, and strong investor validation. While risks and termination clauses are present, the overall tone and stated benefits suggest a strong positive sentiment regarding the future prospects of the combined entity.

Positives

• The strategic combination creates a market-leading mental health company focused on rapid-acting and accessible psychedelic treatments.
• The combined pipeline is synergistic and fully owned, featuring proprietary compounds with convenient administration routes and short time-in-clinic.
• Near-term clinical milestones include topline data from Beckley Psytech's BPL-003 Phase 2b trial in treatment-resistant depression (TRD) expected in mid-2025, representing a significant value inflection point.
• The BPL-003 study is noted as the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate it in the U.S.
• The transaction is expected to provide cash runway through multiple Phase 2 clinical catalysts.
• The combined entity will benefit from near and long-term operational synergies.
• A strong intellectual property (IP) portfolio is established, with granted U.S. patents extending to 2043.
• The unified vision and team are expected to accelerate the development and commercialization of transformative mental health treatments.
• The concurrent $30 million private placement from existing investors (Ferring Ventures S.A. and Adage Capital Partners LP) further validates the strength and potential of this combination.

Negatives

• The acquisition is subject to shareholder approval and other customary closing conditions, which could delay or prevent completion.
• Break fees of $4 million or $10 million are payable by atai under certain termination scenarios related to clinical trial milestones or shareholder approval.
• The ELE-101 asset, which is a clinical-stage compound for Major Depressive Disorder, will be carved out and not acquired as part of the transaction.

Risks

• The closing of the acquisition is subject to the satisfaction of closing conditions, including approval by atai shareholders and the Warranty Condition related to Beckley Psytech's representations and warranties.
• Failure to obtain shareholder approval by the Longstop Date (six months from SPA date, with a potential 90-day extension) could lead to termination of the agreement and a $10 million break fee payable by atai.
• If certain milestones for Beckley Psytech's BPL-003 Phase 2b clinical trial are not met, and atai's boards change their recommendation for shareholder approval, atai can terminate the SPA and pay a $4 million break fee.
• The Warranty Condition requires certain business and seller warranties to be true and accurate at closing, with inaccuracies potentially leading to termination if they have a material adverse effect on Beckley Psytech (value in excess of $25 million).
• Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, as described in atai's most recent Annual Report on Form 10-K.
• The lock-up provisions on newly issued shares and Apeiron's shares could affect market liquidity for a period.

Future Outlook

The combined company, 'Atai Beckley,' aims to accelerate the development and commercialization of transformative mental health treatments, leveraging a synergistic pipeline of rapid-acting psychedelic compounds. Key near-term catalysts include topline data from the BPL-003 Phase 2b trial in mid-2025. The company expects to have cash runway through multiple Phase 2 clinical catalysts and plans to integrate its operations to achieve financial and operational synergies. There is also a potential future transaction to move the company's legal and tax domicile to Delaware.

Management Comments

• Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-Founder of atai: "Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic."
• Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-Founder of atai: "With a unified vision and a synergistic pipeline, we believe we are well-positioned to unlock the strategic value of our clinical development programs for both patients and shareholders. Together, we plan to move confidently towards our goal of bringing innovative interventional psychiatry therapies to patients in need of new treatments."
• Cosmo Feilding Mellen, Chief Executive Officer and Co-Founder of Beckley Psytech: "This combination brings together two highly complementary pipelines to create a market leader at the forefront of psychiatric care. Clinical data has shown the rapid and durable effects of our compounds, as well as their potential to fit within the existing treatment paradigm established by SPRAVATO. We believe that the unified business will be even better positioned to accelerate development, drive long-term value for shareholders, and most importantly deliver meaningful innovation for patients."
• Christian Angermayer, Co-Founder and Chairman of atai: "This transaction marks a pivotal milestone in delivering on the strategic vision we set forth from the start of atai in 2018: to be the leader in the psychedelic space."
• Christian Angermayer, Co-Founder and Chairman of atai: "I am also very pleased to announce the concurrent financing with existing investors from both companies. The continued support from Ferring Ventures, a valued investor in atai, and Adage Capital, a longstanding investor in Beckley, further validates the strength and potential of this combination."

Industry Context

This acquisition signifies a major consolidation in the nascent but rapidly growing psychedelic mental health therapy industry. By combining atai's existing pipeline (VLS-01, EMP-01) with Beckley Psytech's advanced assets (BPL-003), the new 'Atai Beckley' entity aims to establish itself as a global leader, particularly in rapid-acting and accessible psychedelic treatments. The focus on convenient administration and short time-in-clinic for BPL-003 positions the combined company to potentially compete with existing treatments like SPRAVATO, indicating a strategic move towards integrating psychedelic therapies into mainstream healthcare systems. The concurrent financing also reflects continued investor confidence in the long-term potential of this specialized biopharmaceutical sector.

Comparison to Industry Standards

• The combined company's pipeline, particularly BPL-003, is highlighted for its potential to fit within the existing treatment paradigm established by SPRAVATO (esketamine nasal spray), a currently approved rapid-acting antidepressant. This suggests a strategic alignment with established market acceptance for similar delivery methods and treatment profiles.
• The BPL-003 Phase 2b trial is noted as the "largest controlled trial of mebufotenin (5-MeO-DMT)" and the "first and only controlled trial to investigate mebufotenin in the U.S.", positioning it as a pioneering effort in this specific psychedelic compound's development.
• The emphasis on "convenient route of administration and short time-in-clinic" for the combined pipeline's assets suggests a focus on patient accessibility and integration into existing healthcare infrastructure, which is a key industry trend for novel mental health treatments.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing litigation with DemeRx in which atai Life Sciences N.V. is the defendant.

Related Party Transactions

• ATAI made a strategic investment in Beckley Psytech in January 2024, resulting in an approximate one-third ownership stake, prior to this full acquisition.
• Apeiron Investment Group Ltd., the family office of atai's founder Christian Angermayer, owns approximately 21.1% of atai's outstanding Common Shares prior to the PIPE Financing and entered into voting and lock-up agreements related to the transaction.
• Mr. Angermayer was granted options to purchase atai ordinary shares in further consideration of his continued service as a consultant.

Stakeholder Impact

• Shareholders (ATAI): Potential for long-term value creation through synergistic pipeline and market leadership, but also face dilution from new share issuance for acquisition (105,044,902 shares) and PIPE financing (9,993,341 shares + 6,311,006 warrant shares). Lock-up agreements aim to stabilize share price.
• Shareholders (Beckley Psytech): Will exchange their shares for atai common shares, becoming shareholders in the combined entity, subject to lock-up provisions.
• Employees (Combined Entity): The new entity is expected to leverage the expertise, teams, and networks of both organizations, implying potential integration and restructuring. Robert Conley is expected to be employed as Chief Research and Development Officer of the Buyer from Completion.
• Customers/Patients: The combination aims to accelerate the development and commercialization of transformative mental health treatments, potentially leading to new and more accessible therapies for conditions like TRD and AUD.
• Management: A joint leadership team and Board will be formed, leveraging expertise from both organizations, with key appointments like Cosmo Feilding-Mellen and Robert Hershberg to the Supervisory Board.
• Creditors: The $30 million PIPE financing is for general corporate purposes, not directly for the acquisition, which could improve the combined company's liquidity and financial health.

Next Steps

• Closing of the PIPE Financing expected on or about June 3, 2025.
• Topline data from Beckley Psytech's BPL-003 Phase 2b trial in TRD expected in mid-2025.
• Eleusis Holdings Limited and its subsidiaries (holding ELE-101 assets) will be carved out from the Beckley Group prior to the acquisition's closing.
• The acquisition transaction is expected to close in the second half of 2025, subject to atai shareholder approval and other customary closing conditions.
• ATAI shareholders will vote on resolutions to approve the acquisition (including share issuance), appoint certain director nominees, and change the company's name to Atai Beckley N.V.
• ATAI will file a proxy statement on Schedule 14A with the SEC for shareholder approval.
• ATAI will file a registration statement under the Securities Act for the resale of shares issued in the PIPE financing and upon exercise of pre-funded warrants.
• The company plans to move its legal and tax domicile from the Netherlands/Germany to Delaware, subject to certain conditions and shareholder support from Apeiron.
• Cosmo Feilding-Mellen and Robert Hershberg are nominated for appointment to the Supervisory Board upon completion.
• ATAI will convene and hold a general meeting for the purpose of obtaining Shareholder Approval.

Key Dates

Recommendation

Keywords

ATAI Life Sciences, Beckley Psytech, Merger, Acquisition, Psychedelic Therapies, Mental Health, BPL-003, TRD, Treatment-Resistant Depression, 5-MeO-DMT, ELE-101, Major Depressive Disorder, PIPE Financing, Biopharmaceutical, Clinical-stage, Drug Development, Corporate Governance, Share Purchase Agreement, Nasdaq, SEC Filing, Biotech